Scott Gottlieb, MD

Opinion | With China undermining U.S. biotech, here’s how the FDA can counter Lower the costs of development for American scientists, too.

"China has no scientific edge over the United States," @scottgottliebmd.bsky.social writes.

"China has only a policy edge, which derives from its deliberate economic strategy."

YouTube video by CNBC Television Dr. Gottlieb on China's biotech strategy: China has become very adept at following U.S. discoveries

My segment on @cnbc.com Squawk Box today on the shift in drug discovery to China, the threat that it poses to the U.S. biotechnology ecosystem, and policy steps that the U.S. FDA can take to level the playing field for early drug discovery.

YouTube video by CNBC Television Larger trials needed to prove Tylenol, Autism risk correlation: Dr. Scott Gottlieb

My hit on @cnbc.com today on the new actions to address autism and the need to exercise more judgment and caution

youtu.be/B7t9ryBoBfQ

Measles Death Shows How Virus Can Hide in the Brain for Years A school-aged child in Los Angeles County has died from a rare but always fatal complication from a measles infection they acquired when they were an infant who was too young to be vaccinated. Expert...

Measles Death Shows How Virus Can Hide in the Brain for Years www.aol.com/articles/mea...

YouTube video by CNBC Television CDC vaccine panel to meet this week: Here's what's at stake

My appearance on #CNBC today about the #CDC’s #ACIP meeting on vaccines, which could bring action by HHS to remove the MMRV vaccine, eliminate the recommendation for Hep B in newborns, and narrow use of Covid vaccines.

My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+

We risk a return of communicable diseases in children.

www.youtube.com/watch?v=00cI...

My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+

We risk a return of communicable diseases in children.

www.youtube.com/watch?v=00cI...

YouTube video by CNBC Television Dr. Scott Gottlieb reacts to RFK Jr. linking autism to Tylenol

My segment from Friday in @cnbc.com on vaccine policy

youtu.be/J9FVvNR-n_E

I’ll be coming up on @SquawkCNBC at 6:30 to discuss vaccine safety and public health.

Reforming the FDA to Meet Today's Innovation Challenges Friday, Sept. 19, 9-11 am ET USC Capital Campus Hosted by USC Schaeffer

📅 Join us Sept. 19 for a conference on #FDA policy reforms aimed at reducing drug development costs and getting valuable new treatments to patients faster.

Speakers: @scottgottliebmd.bsky.social, Janet Woodcock, Ken Drazan, Lowell Schiller & more

➡️Registration: schaeffer.usc.edu/event/reform...

Securing America’s Pharmaceutical Innovation Edge This JAMA Forum discusses challenges to the US’s standing as a global leader in biomedical innovation from China, in the context of recent reductions in funding for biomedical research by the federal ...

My editorial in JAMA Health Forum: To support the academic research enterprise, we should pursue regulatory reforms that enable institutions to advance more of their discoveries to patients and, in doing so, capture more economic value of innovations they achieve

jamanetwork.com/journals/jam...

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure Australia-listed CSL, which has a significant portion of its business in the U.S., announced its intention to simplify its operating structure amid a challenging and volatile environment.

CSL, a major manufacturer of flu vaccine, is spinning off its entire vaccine unit and cutting up to 15% of its staff. Influenza vaccine uptake is off by about 10%

www.wsj.com/business/csl...

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force

insights.citeline.com/pink-sheet/a...

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force

insights.citeline.com/pink-sheet/a...

FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers

insights.citeline.com/pink-sheet/a...

YouTube video by Face the Nation Dr. Scott Gottlieb on HHS Secretary RFK Jr.'s newly appointed vaccine advisory panel

My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.

YouTube video by Face the Nation Dr. Scott Gottlieb on HHS Secretary RFK Jr.'s newly appointed vaccine advisory panel

My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.

YouTube video by CNBC Television Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years

My segment today on cnbc.com on the CDC’s ACIP meeting.

YouTube video by CNBC Television Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years

My segment today on cnbc.com on the CDC’s ACIP meeting.

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com

Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.

My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.

My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

How to stop the shift of drug discovery from the U.S. to China U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

My op-ed on the large shift of drug discovery moving to China and policy steps the U.S. can take to keep the innovation economy in America. "Five years ago, U.S. drug makers didn’t license any new drugs from China. By 2024, one-third came from Chinese biotech"

How to stop the shift of drug discovery from the U.S. to China U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

How to stop the shift of drug discovery from the U.S. to China www.statnews.com/2025/05/06/h... from @scottgottliebmd.bsky.social via @statnews.com

How to stop the shift of drug discovery from the U.S. to China U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

My op-ed on the large shift of drug discovery moving to China and policy steps the U.S. can take to keep the innovation economy in America. "Five years ago, U.S. drug makers didn’t license any new drugs from China. By 2024, one-third came from Chinese biotech"

Whooping cough cases are rising again in the US Preliminary data from the U.S. Centers of Disease Control and Prevention says the U.S. has seen 8,485 cases of whooping cough in 2025.

Whooping cough cases are rising, and doctors are bracing for another tough year. There have been 8,485 cases reported so far in 2025, according to preliminary data from the CDC. That’s twice as many cases as this time last year.

apnews.com/article/whoo...

Steve Usdin writing in BioCentury: “It’s official: FDA says its cuts are delaying drug regulation — Layoffs, lack of access to journals slow response FDA says”

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs The FDA Reduction-in-Force (Termination)—or “RIF(T)”—announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIF’d.  As the dust begins to se…

This FDA office enabled all of the first time generic drug approvals in the U.S. Their work helped substantially lower drug costs and increase competition during President Trump’s first term, including spearheading approval of the first generic EpiPen in 2018. This office has now been eliminated

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs The FDA Reduction-in-Force (Termination)—or “RIF(T)”—announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIF’d.  As the dust begins to se…

This FDA office enabled all of the first time generic drug approvals in the U.S. Their work helped substantially lower drug costs and increase competition during President Trump’s first term, including spearheading approval of the first generic EpiPen in 2018. This office has now been eliminated